JASN:睡前服降压药效果或更佳(附点评)

2011-11-03 MedSci原创 MedSci原创

 西班牙研究显示,慢性肾病(CKD)伴高血压患者,睡前服用至少一种降压药物可更好地控制血压并降低心血管事件风险。论文10月24日在线发表于《美国肾脏学会杂志》(J Am Soc Nephrol)。   该开放性试验共纳入晨起服用降压药和睡前至少服用一种降压药的CKD伴高血压患者661例,分别测量患者基线、调整治疗策略3个月后(每位患者至少每年一次)48小时动态血压,

 西班牙研究显示,慢性肾病(CKD)伴高血压患者,睡前服用至少一种降压药物可更好地控制血压并降低心血管事件风险。论文10月24日在线发表于《美国肾脏学会杂志》(J Am Soc Nephrol)。   该开放性试验共纳入晨起服用降压药和睡前至少服用一种降压药的CKD伴高血压患者661例,分别测量患者基线、调整治疗策略3个月后(每位患者至少每年一次)48小时动态血压,平均随访时间5.4年。结果显示,至少睡前服用一种降压药的患者校正后总心血管事件风险约为晨起服用所有降压药患者的 1/3。睡前服用降压药可显著降低心血管死亡、心肌梗死和卒中的混合风险。此外,睡前服药的患者睡眠期间平均血压显著降低,动态血压监测显示该人群血压控制比例优于晨起服药患者(56%对45%)。睡眠期间收缩压每降低5 mmHg,随访期间患者心血管事件风险可降低14%。   ■专家点评   降压药物的服用时间没有固定模式   上海交通大学医学院附属瑞金医院心脏科 施仲伟   大多数高血压患者在晨起后服用降压药物,这与生活习惯有关,也因为他们白天的血压明显高于夜间(即杓型血压)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941213, encodeId=89d21941213cd, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Feb 23 16:18:00 CST 2012, time=2012-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3612, encodeId=276c3612ac, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=682d366, createdName=yangwen5709, createdTime=Mon Nov 07 21:50:00 CST 2011, time=2011-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291759, encodeId=476f1291e59ef, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548021, encodeId=35da15480217f, content=<a href='/topic/show?id=175ee2964f6' target=_blank style='color:#2F92EE;'>#睡前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72964, encryptionId=175ee2964f6, topicName=睡前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e40613986188, createdName=ms6323715314570549, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672279, encodeId=8ac716e227909, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue Apr 03 07:18:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-02-23 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941213, encodeId=89d21941213cd, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Feb 23 16:18:00 CST 2012, time=2012-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3612, encodeId=276c3612ac, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=682d366, createdName=yangwen5709, createdTime=Mon Nov 07 21:50:00 CST 2011, time=2011-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291759, encodeId=476f1291e59ef, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548021, encodeId=35da15480217f, content=<a href='/topic/show?id=175ee2964f6' target=_blank style='color:#2F92EE;'>#睡前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72964, encryptionId=175ee2964f6, topicName=睡前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e40613986188, createdName=ms6323715314570549, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672279, encodeId=8ac716e227909, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue Apr 03 07:18:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2011-11-07 yangwen5709

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941213, encodeId=89d21941213cd, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Feb 23 16:18:00 CST 2012, time=2012-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3612, encodeId=276c3612ac, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=682d366, createdName=yangwen5709, createdTime=Mon Nov 07 21:50:00 CST 2011, time=2011-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291759, encodeId=476f1291e59ef, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548021, encodeId=35da15480217f, content=<a href='/topic/show?id=175ee2964f6' target=_blank style='color:#2F92EE;'>#睡前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72964, encryptionId=175ee2964f6, topicName=睡前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e40613986188, createdName=ms6323715314570549, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672279, encodeId=8ac716e227909, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue Apr 03 07:18:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941213, encodeId=89d21941213cd, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Feb 23 16:18:00 CST 2012, time=2012-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3612, encodeId=276c3612ac, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=682d366, createdName=yangwen5709, createdTime=Mon Nov 07 21:50:00 CST 2011, time=2011-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291759, encodeId=476f1291e59ef, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548021, encodeId=35da15480217f, content=<a href='/topic/show?id=175ee2964f6' target=_blank style='color:#2F92EE;'>#睡前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72964, encryptionId=175ee2964f6, topicName=睡前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e40613986188, createdName=ms6323715314570549, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672279, encodeId=8ac716e227909, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue Apr 03 07:18:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1941213, encodeId=89d21941213cd, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Thu Feb 23 16:18:00 CST 2012, time=2012-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3612, encodeId=276c3612ac, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=682d366, createdName=yangwen5709, createdTime=Mon Nov 07 21:50:00 CST 2011, time=2011-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291759, encodeId=476f1291e59ef, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548021, encodeId=35da15480217f, content=<a href='/topic/show?id=175ee2964f6' target=_blank style='color:#2F92EE;'>#睡前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72964, encryptionId=175ee2964f6, topicName=睡前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e40613986188, createdName=ms6323715314570549, createdTime=Sat Nov 05 13:18:00 CST 2011, time=2011-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672279, encodeId=8ac716e227909, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Tue Apr 03 07:18:00 CST 2012, time=2012-04-03, status=1, ipAttribution=)]
    2012-04-03 lsndxfj

相关资讯

朱鼎良:解读中国高血压防治指南

  在2011长城国际心脏病学会议上,来自上海瑞金医院的朱鼎良教授对中国高血压防治指南的重点内容进行了解读,包括我国人群高血压特点、血压测量、心血管总体危险分层、降压治疗的血压目标以及联合用药方面。   朱鼎良教授在报告中指出,2010年中国高血压防治指南(以下简称2010指南)具有权威性、科学性、新颖性、特色性和实用性的特点。2010指南增添了儿童与青少年高血压等内容。   我国高血压人群有

高血压前期,糖尿病与卒中关联研究进展

高血压前期卒中风险增加55%        一项来自加利福尼亚大学的新研究结果表明:高血压前期可增加卒中风险55%。[Neurology.2011-10-4;77(14):1330-7]        高血压前期指血压处于正常血压的上限范围内:SBP为120~139mmHg,DBP为80~89mmHg。众所

ARB为高血压一线治疗?

  欧洲心脏病学会(ESC)2011争议话题     正方   巴黎吉雷尔德(Girerd)教授陈述了相关证据支持。   1. 欧洲高血压学会(ESH)/ESC指南推荐ARB适用于抗高血压起始和维持治疗。   2. 欧洲临床实践中使用ARB治疗高血压较普遍。   3. ARB降低收缩压和舒张压疗效强。   4. 大部分ARB具有长效性,可以1次/

KYOTO HEART研究:缬沙坦对伴CKD高血压者有益

  8月28日,在欧洲心脏病学会(ESC2011)临床研究更新会上,日本学者Takahisa Sawada报告的多中心、双平行治疗组比较、效应依赖性剂量调整设计研究(KYOTO HEART研究)显示,高危高血压患者的慢性肾脏病(CKD)与心血管(CV)事件显著相关,CKD-3和CKD-4期之间的事件发生率升高。而缬沙坦对合并CKD的高危高血压患者有效,主要益处在于预防心衰和肾血

ASCOT-LLA研究:前期降脂治疗对高血压患者有长期益处

  8月28日,在欧洲心脏病学会(ESC2011)临床研究更新会上,英国学者Peter S Sever报告了盎格鲁-斯堪的那维亚心脏终点研究降脂分支(ASCOT-LLA)终止后继续随访8年的结果。证实对于高血压患者,前期接受阿托伐他汀治疗能够产生长期益处。   ASCOT-LLA研究因阿托伐他汀较安慰剂显著获益而在2003年提前终止,表现为包括冠心病(HR 0.64

高血压临床热点汇集

  围术期高血压管理   希腊雅典的C Tsioufis教授指出,术前对患者的评估是检查和优化高血压控制的时机。除病史、体检、实验室评估和心电图(ECG)外,诊断方法的范围依赖于手术的紧迫性、手术特定的危险,以及存在活动性心脏症状和其他危险因素、患者能动性等。   与血压控制不良者相比,血压控制良好的患者较少伴发术中血压不稳定和术后并发症。理想情况下,在择期手术前几个月应使血压正常化。对于高血